— Why it moved
Why SNGX Stock Fizzled Today — May 27, 2026
The Ebola-vaccine pop happened before the bell; by the time the stock was flagged it was already rolling over.
## What moved it Soligenix put out an update saying its ThermoVax thermostable filovirus vaccine work could be a starting point for a Bundibugyo Ebola vaccine. That was the hook, and it doubled the stock in the premarket. The problem for the day session: the whole move was already spent by the bell.
## The mechanics Sub-dollar-turned-dollar biotech, float under 10M shares, $13M cap — the ingredients for a violent premarket spike on outbreak news. But a platform "could apply" statement is about as early-stage as a catalyst gets, and that kind of thin story fades as fast as it spikes.
## Numbers - Cap: ~$13M / float: ~9.8M shares - Day volume: ~246M (~54x avg) - Prev close: $0.51 → gap +92% - 52w range: $0.28–$6.23
## Where it ended up Stock Pulse flagged it at 8:32 AM, $1.09 — after the premarket high near $1.30 had already come and gone. It managed only $1.13 by 9:45 AM, up under 4%, before sliding all day to close $0.87, down 21% versus the alert. The catch here was the tail end of a pop, not the pop itself.
## Reality check - The alert landed after the move; the real premarket high was hours earlier. - No approved product, and an Ebola-platform tie-in that's aspirational, not a program with data. - This is a post-mortem on a premarket squeeze that had nothing left. Not a reason to buy.